Brief: Nkgen Biotech Presents Additional Phase 1 Clinical Trial Data In Alzheimer’S Disease At The Tau2024 Global Conference
25/03/2024 22:00
March 25 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN BIOTECH PRESENTS ADDITIONAL PHASE 1 CLINICAL TRIAL
DATA IN
ALZHEIMER’S DISEASE AT THE TAU2024 GLOBAL CONFERENCE
Source text for Eikon: ID:nGNX8Sgt3D
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program